Ebola future or investigational therapies
|
Ebola Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Postmortem Care |
|
Case Studies |
|
Ebola future or investigational therapies On the Web |
|
American Roentgen Ray Society Images of Ebola future or investigational therapies |
|
Risk calculators and risk factors for Ebola future or investigational therapies |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Michael Maddaleni, B.S.
Overview
There are promising results for antisense prevention therapies in monkey studies. This new therapy has shown promise when it comes to treating accidental infections with the ebola virus, which would be a very important feat, especially for people working with ebola in laboratories[1]. The research, which took place under the supervision of the U.S. Army Medical Research Institute of Infectious Diseases, uses a specific group of compounds called antisense phosphorodiamidate morpholino oligomers, or PMOs[1]. The scientists eventually developed a therapy, which was referred to as AVI-6002, that was able to demonstrate a survival rate of approximately 90% in pre and post-exposure animals[1]. Using this new treatment, 5 out of 8 monkeys were able to survive exposure to the ebola virus, which are very promising results.
References
- ↑ 1.0 1.1 1.2 "Novel 'antisense' therapies protect primates from lethal Ebola and Marburg viruses". Retrieved 2012-04-20.